Cellular, Acellular, and Matrix-Like Placental Products for Diabetic Foot Ulcers: A 12-Week Randomised-Trial Meta-Analysis.
George Theodorakopoulos, David G Armstrong
✦ AI-curated · Sources linked
In 30 seconds
This meta-analysis evaluated the effectiveness of placental-derived cellular, acellular, and matrix-like products (CAMPs) as adjuncts to standard care for diabetic foot ulcers (DFUs) in adults. The analysis included 14 randomised trials, revealing that complete wound closure at 12 weeks occurred in 59.0% of participants treated with CAMPs compared to 35.8% in the control group, resulting in a risk ratio of 1.70 (95% CI 1.31-2.20).
Key findings
- Complete closure occurred in 59.0% of product-treated participants versus 35.8% in controls.
- Adjunctive CAMPs increased the likelihood of closure with a risk ratio of 1.70.
- The analysis included 14 randomised articles with 944 participants providing data.
- Moderate heterogeneity was observed (I² = 51.9%).
Why it matters
The findings suggest that adjunctive use of placental-derived products can significantly enhance healing outcomes for diabetic foot ulcers, which is crucial for improving patient quality of life and reducing complications associated with these chronic wounds.